Curi RMB Capital LLC Sells 192 Shares of Novo Nordisk A/S (NYSE:NVO)

Curi RMB Capital LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,096 shares of the company’s stock after selling 192 shares during the quarter. Curi RMB Capital LLC’s holdings in Novo Nordisk A/S were worth $1,559,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of NVO. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S during the second quarter worth $25,000. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Orion Capital Management LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter worth approximately $26,000. Gilliland Jeter Wealth Management LLC lifted its holdings in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. boosted its stake in Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $101.74 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market cap of $456.56 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 1.31 and a beta of 0.42. The business has a 50 day simple moving average of $119.17 and a 200 day simple moving average of $129.75. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15.

Analysts Set New Price Targets

Several brokerages have commented on NVO. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.